Healthcare

We create and invest in leading companies in therapeutics, medtech, and health IT & services.

27

Twenty Seven products and drugs approved

With another 8 drugs in phase 3. Typically, only 1 in 5,000 drugs makes it from idea to market.

23

Twenty three companies created from scratch

If we can't find a company solving an important problem, we create one ourselves - just like we did with Innovent, Denali, and Beam to name a few.

$1.8B

Nearly two billion dollars over seven funds

Without the pressure of fundraising from outside investors, we're privileged to champion companies that help heal the world.

Category

Region

Status

  • Gu Sheng Tang (“GST”) is a Guangzhou, China-based healthcare services provider that operates a chain of private clinics specializing in traditional Chinese medicine. Learn more at www.gstzy.cn.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      Guangzhou, China

    • Year Invested

      2015

    • Team

  • Huan Qui Li Kang Technology Co., Ltd. (“HQ”) is an early stage hemostatic product manufacturer in China.

  • Eyebright Medical Technology Co., Ltd. (SHA: 688050) is an emerging leader in the ophthalmologic device market in China. Learn more at www.ebmedical.com.

    • Category

      • MedTech
    • Status

      • Public
    • Location

      Beijing, China

    • Year Invested

      2015

    • Team

  • Zhejiang Bang Er Medical Investment Management Co., Ltd. is a leading private medical service provider that operates several private hospitals specializing in orthopedic care and related services in China. Learn more at www.zjbanger.com.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      Zhejiang, China

    • Year Invested

      2015

    • Team

  • Precision Biosciences (NASDAQ:DTIL) is developing a gene-editing platform based on their proprietary ARCUS nuclease for multiple applications with a focus on human therapeutics. Learn more at www.precisionbiosciences.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Durham, NC

    • Year Invested

      2015

  • Cygnus Hospitals is an asset-light chain of 10 hospitals based in North India, focusing on select higher-secondary and tertiary-care specialties. Learn more at www.cygnushospitals.com.

  • Quartet Health is developing care coordination software and services designed to improve clinical outcomes and reduce the cost of care for patients where behavioral health is the primary or a comorbid condition. Learn more at www.quartethealth.com

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      New York, NY

    • Year Invested

      2015

    • Team

  • Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies. Learn more at www.cariboubio.com.

  • Semma Therapeutics is a regenerative medicine company founded to develop transformative stem cell-derived therapies to provide a functional cure for patients with diabetes. This company was acquired by Vertex in 2019.

  • Stride Health is an early-stage healthcare IT company developing a multi-carrier, private health insurance marketplace for the individual segment. Learn more at www.stridehealth.com.

    • Category

      • FinTech
      • Health IT/Services
    • Status

      • Private
    • Location

      San Francisco, CA

    • Year Invested

      2014

    • Team

  • TraceLink the world’s largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes. Learn more at www.tracelink.com.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      Wakefield, MA

    • Year Invested

      2015

    • Team

  • WellAir is a global company working to disinfect and purify indoor air for optimal human health and building performance. Learn more at www.wellairsolutions.com.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      Dublin, Ireland

    • Year Invested

      2014

    • Team

  • Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease. Learn more at www.aviditybiosciences.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      San Diego, CA

    • Year Invested

      2014

  • Surface Oncology (NASDAQ:SURF) is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47.  Learn more at www.surfaceoncology.com.

  • Cogent Biosciences (NASDAQ:COGT) (formerly Unum Therapeutics) has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. Learn more at www.cogentbio.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, MA

    • Year Invested

      2014

  • Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Learn more at www.adaptimmune.com.

  • US HealthVest provides specialized, high quality psychiatric care, including substance abuse treatment, through a broad range of inpatient and outpatient programs. Learn more at www.ushealthvest.com.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      New York, NY

    • Year Invested

      2013

    • Team

  • Lumere (formerly Procured Health) is an organization comprised of clinicians, researchers, pharmacists and strategic thought leaders focused on helping health systems eliminate unwarranted clinical variation and cut unnecessary costs—specifically related to device and drug selection and utilization. This company was acquired by Global Healthcare Exchange (GHX) in 2020.

    • Category

      • Health IT/Services
    • Status

      • Acquired
    • Location

      Chicago, IL

    • Year Invested

      2012

    • Team

  • Liazon is a provider of web-based private benefits exchanges to small and medium-sized businesses. Liazon was acquired by Towers Watson in 2013. Learn more at www.liazon.com.

    • Category

      • Health IT/Services
    • Status

      • Acquired
    • Location

      Buffalo, NY

    • Year Invested

      2012

    • Team

  • Kyruus uses the science of data-driven clinical matching to ensure that patients are being matched to the right provider and enabling healthcare systems to coordinate care delivery across their provider networks. Learn more at www.kyruus.com.

    • Category

      • Health IT/Services
    • Status

      • Private
    • Location

      Boston, MA

    • Year Invested

      2012

    • Team

  • Iora Health is building a different kind of health system to deliver high impact, relationship based care. Learn more at www.iorahealth.com.

  • ViewRay (NASDAQ: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. Which uses a high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology.  Learn more at www.viewray.com.

  • Trivitron Healthcare is India’s largest, national wholesale distributor and after-sales support provider of medical equipment and devices. Learn more at www.trivitron.com.

  • TCT Medical is a diagnostic company based in China which provides high quality diagnostic tests, primarily in the women’s health arena. TCT Medical was acquired by Hologic.

    • Category

      • MedTech
    • Status

      • Acquired
    • Location

      Beijing, China

    • Year Invested

      2009

    • Team

  • MDDF is a medical device company focused on the manufacturing, development, and commercialization of high quality, affordably priced cardiovascular and general surgery medical devices for the Chinese market.

     

    • Category

      • MedTech
    • Status

      • Private
    • Location

      Beijing, China

    • Year Invested

      2011

    • Team

  • Ivenix is dedicated to eliminating infusion-related patient harm, uniquely positioned at the crossroads of healthcare IT and infusion delivery. Learn more at www.ivenix.com.

  • BioRegen Biomedical is a fully integrated medical product company based on a proprietary technology platform. BioRegen is developing and commercializing high quality hyaluronic acid (“HA”) based products for the Chinese market. Learn more at www.bioregenmed.com.

    • Category

      • MedTech
    • Status

      • Private
    • Location

      China

    • Year Invested

      2010

    • Team

  • BioConnect Systems was a medical device company that developed a CE-Marked product for improving dialysis access  surgery. Learn more at www.bioconnectsystems.com.

  • Better Life Medical is a fully-integrated hearing aid manufacturer developing and commercializing novel digital programmable hearing aid solutions for the Chinese market. Learn more at www.goblm.com.cn/.

  • Amphora Medical was a medical device technology company developing minimally invasive products to restore the quality of life of people suffering from Overactive Bladder Syndrome.

  • Accuri Cytometers was a life sciences tools company that democratized flow cytometry for medical and pharmaceutical research. Accuri Cytometers was acquired by Becton Dickinson.

  • Vicept Therapeutics is a dermatology specialty pharmaceutical company developing a topical prescription product for the treatment of the chronic skin condition, Rosacea. Vicept Therapeutics was acquired by Allergan.

     

  • Ultragenyx (NASDAQ: RARE) a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. Learn more at www.ultragenyx.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Novato, CA

    • Year Invested

      2011

    • Team

  • Transave is focused on improving the treatment of serious lung diseases through the company’s next generation, proprietary liposomal delivery technology.

     

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Monmouth Junction, NJ

    • Year Invested

      2006

    • Team

  • Topaz Pharmaceuticals is a specialty pharmaceutical company developing a topical prescription product, Sklice, for the treatment of head lice. Topaz Pharmaceuticals was acquired by Sanofi.

     

  • Tetraphase (NASDAQ: TTPH)  is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVATM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Learn more at www.tphase.com.

  • Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals. Learn more at www.symbiomix.com.

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      Newark, NJ

    • Year Invested

      2013

    • Team

  • RespiVert was a drug discovery and development company focused on inhaled therapies for severe respiratory disease. RespiVert was acquired by Centocor Ortho Biotech – a division of Johnson & Johnson.

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      London, UK

    • Year Invested

      2007

    • Team

  • ReGenX Biosciences (NASDAQ: RGNX)  is a leading AAV (adeno-associated virus) gene therapy company with a broad platform technology based on its proprietary NAV vector technology platform Learn more at www.regenxbio.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Washington, D.C.

    • Year Invested

      2013

  • Pulmocide is a biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Learn more at www.pulmocide.com.

  • Proteostasis Therapeutics (NASDAQ: PTI)  is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Learn more at www.proteostasis.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, MA

    • Year Invested

      2008

    • Team

  • NovaMed Pharmaceuticals is a revenue-generating specialty pharmaceutical company focused on the commercialization of branded innovative therapies for diseases with high unmet medical need in China, including oncology, urology, and cardiovascular.  NovaMed was acquired by SciClone.

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      Shanghai, China

    • Year Invested

      2007

  • NextWave Pharmaceuticals is a specialty pharmaceutical company seeking to create and promote differentiated products in the pediatric market. NextWave Pharmaceuticals was acquired by Pfizer.

  • Mersana Therapeutics (NASDAQ:MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines. Learn more at www.mersana.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, MA

    • Year Invested

      2005

    • Team

  • LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      Bozeman, MT

    • Year Invested

      2008

    • Team

  • Laurus Labs (NSE:LAURUSLABS) is a leading manufacturer of Active Pharmaceutical Ingredients (API) for anti-retroviral (HIV-AIDS), oncology, nutraceutical and several other products, with a customer base that spans top-tier generic pharmaceutical companies in India and abroad. Learn more at www.lauruslabs.com.

  • Ironwood Pharmaceuticals (NASDAQ:IRWD) developed  linaclotide, a first-in-class therapy that received FDA approval for both irritable bowel syndrome and chronic constipation. Learn more at www.ironwoodpharma.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, MA

    • Year Invested

      2002

    • Team

  • Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.  Ikano was acquired by UCB.

  • Innovent Biologics (1801.HK) has built a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases. Learn more at www.innoventbio.com.

  • Hua Medicine (2552.KHK) is a leading clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Learn more at www.huamedicine.com.

  • Hile (603718.SS) is a leading animal vaccine manufacturer that specializes in sales, marketing and commercialization of animal vaccine products in China. Learn more at www.hile-bio.com/.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Shanghai, China

    • Year Invested

      2010

  • FoldRx Pharmaceuticals focuses on creating disease modifying drug therapies for diseases of protein misfolding. FoldRx developed, tafamidis, the first-in-class therapy approved or TTR amyloidosis. FoldRx was acquired by Pfizer.

  • Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ:RARE).

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      Cambridge, MA

    • Year Invested

      2013

    • Team

  • Coherus Biosciences (NASDAQ: CHRS) is a biosimilar-focused, biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize high-quality biosimilar therapeutics worldwide. Learn more at www.coherus.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Redwood City, CA

    • Year Invested

      2014

  • CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.

  • Blueprint Medicines (NASDAQ: BPMC) is a precision therapy company striving to improve human health. Learn more at www.blueprintmedicines.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, MA

    • Year Invested

      2012

    • Team

  • Bikam Pharmaceuticals is a drug discovery company focused on developing novel therapies for diseases of the eye with exceptionally high unmet medical need. Bikam Pharmaceuticals was acquired by Shire.

     

    • Category

      • Therapeutics
    • Status

      • Acquired
    • Location

      Cambridge, MA

    • Year Invested

      2007

    • Team

  • Adagene (Nasdaq: ADAG) is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. Learn more at www.adagene.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Suzhou, China

    • Year Invested

      2011

    • Team

  • Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. Learn more at www.aclaristx.com.

  • Acacia Pharma (EURONEXT:ACPH) is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Learn more at www.acaciapharma.com.

    • Category

      • Therapeutics
    • Status

      • Public
    • Location

      Cambridge, United Kingdom

    • Year Invested

      2013

    • Team